Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Semaglutide cycle length: what human studies ran

FDA-approvedAHuman trial evidence
Short answer: Semaglutide has no "cycle". As an approved drug it is used as its label and a prescriber direct.

Treatment and follow-up in human studies

  1. Ozempic glycemic-control trials summarised on the label administered once-weekly semaglutide 0.5 mg, 1 mg or 2 mg for 30 to 56 weeks; SUSTAIN 6 (3,297 participants) randomized to 0.5 mg or 1 mg or placebo for a minimum observation time of 2 years, and FLOW (3,533 participants, 1 mg or placebo) followed participants for a median of 41 months 1.
  2. Wegovy weight-reduction trials on the label: 68-week trials (16-week escalation to 2.4 mg, then 52 weeks maintenance); Studies 8 and 9 escalated to 2.4 mg or 7.2 mg over 20 weeks followed by 52 weeks maintenance (72 weeks in total); the oral 25 mg tablet trial (Study 7) lasted 64 weeks (12-week escalation, 52-week maintenance); the pediatric trial lasted 68 weeks after a 12-week lifestyle run-in 2.
  3. In the Wegovy cardiovascular outcomes trial (Study 1, NCT03574597; 17,604 participants), patients were titrated to 2.4 mg over 16 weeks and the median follow-up was 41.8 months; the MASH trial (Study 11, NCT04822181) is a 240-week trial with efficacy assessed at week 72 2.
  4. Oral semaglutide glycemic trials on the Rybelsus label lasted 26 weeks; the cardiovascular outcomes trial of semaglutide tablets 14 mg versus placebo (Trial 7, 9,650 participants) had a median follow-up of 49.6 and 49.4 months in the semaglutide and placebo groups 3.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Semaglutide combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Semaglutide cycle length?
No cycle is defined. Semaglutide is an approved drug whose label describes treatment under a prescriber's care; the label, not a cycle, governs duration.
What is the longest human study of Semaglutide?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Semaglutide dosing reference Full research page

References

  1. OZEMPIC (semaglutide) injection, prescribing information FDA label (DailyMed). 2026
  2. WEGOVY (semaglutide) injection and tablets: prescribing information (Novo Nordisk), DailyMed set ID ee06186f-2aa3-4990-a760-757579d8f77b FDA label (DailyMed). 2026
  3. RYBELSUS and OZEMPIC (semaglutide) tablets: prescribing information (Novo Nordisk), DailyMed set ID 27f15fac-7d98-4114-a2ec-92494a91da98 FDA label (DailyMed). 2026
  4. Drugs@FDA application records for NDA 209637 (Ozempic), NDA 213051 (Rybelsus) and NDA 215256 (Wegovy): original approval dates Drugs@FDA (via openFDA). 2026
  5. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) N Engl J Med. 2021
  6. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) N Engl J Med. 2016
  7. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) N Engl J Med. 2023
  8. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) N Engl J Med. 2024
  9. WADA publishes 2027 Prohibited List (news release, 21 September 2026) WADA. 2026
  10. International Standard Prohibited List 2026 WADA Prohibited List. 2026